Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Thromb Haemost. 2014 Jul 17;12(8):1283–1293. doi: 10.1111/jth.12633

Fig. 2. Platelet-FVIII expression in 2bF8/MGMT-transduced recipients (MOI of 1).

Fig. 2

Platelets were isolated from peripheral blood from 2bF8/MGMT-transduced recipients before and after BG/BCNU drug selection treatments. The levels of platelet-FVIII were determined by a chromogenic assay on platelet lysates. The levels of platelet-FVIII expression pre-BCNU treatment were averaged from the time points before BG/BCNU treatments and the levels post-BCNU were averaged from three or more time points after the final BG/BCNU treatment. (A) Platelet-FVIII expression in 2bF8/MGMT-transduced recipients pre-conditioned with 660 cGy TBI. (B) Platelet-FVIII expression in 2bF8/MGMT-transduced recipients pre-conditioned with 440 cGy TBI. These data demonstrate that MGMT-mediated in vivo drug-selection treatments can efficiently enhance platelet-FVIII expression in 2bF8/MGMT-transduced recipients.